Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment
Open Access
- 26 February 2019
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 10, 75
Abstract
Bone homeostasis displays a circadian rhythm with increased resorption during the night time as compared to day time, a difference that seems—at least partly—to be caused by food intake during the day. Thus, ingestion of a meal results in a decrease in bone resorption, but people suffering from short bowel syndrome lack this response. Gut hormones, released in response to a meal, contribute to this link between the gut and bone metabolism. The responsible hormones appear to include glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), known as incretin hormones due to their role in regulating glucose homeostasis by enhancing insulin release in response to food intake. They interact with their cognate receptors (GIPR and GLP-1R), which are both members of the class B G protein-coupled receptors (GPCRs), and already recognized as targets for treatment of metabolic diseases, such as type 2 diabetes mellitus (T2DM) and obesity. Glucagon-like peptide-2 (GLP-2), secreted concomitantly with GLP-1, acting via another class B receptor (GLP-2R), is also part of this gut-bone axis. Several studies, including human studies, have indicated that these three hormones inhibit bone resorption and, moreover, that GIP increases bone formation. Another hormone, peptide YY (PYY), is also secreted from the enteroendocrine L-cells (together with GLP-1 and GLP-2), and acts mainly via interaction with the class A GPCR NPY-R2. PYY is best known for its effect on appetite regulation, but recent studies have also shown an effect of PYY on bone metabolism. The aim of this review is to summarize the current knowledge of the actions of GIP, GLP-1, GLP-2, and PYY on bone metabolism, and to discuss future therapies targeting these receptors for the treatment of osteoporosis.Keywords
This publication has 126 references indexed in Scilit:
- Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptorJournal of Endocrinology, 2013
- European guidance for the diagnosis and management of osteoporosis in postmenopausal womenOsteoporosis International, 2012
- Peptide YY Regulates Bone Remodeling in Mice: A Link between Gut and Skeletal BiologyPLOS ONE, 2012
- Estrogen and peptide YY are associated with bone mineral density in premenopausal exercising womenBone, 2011
- Receptors and effects of gut hormones in three osteoblastic cell linesBMC Physiology, 2011
- Peptide YY in adolescent athletes with amenorrhea, eumenorrheic athletes and non-athletic controlsBone, 2009
- Peptide YY (PYY) levels and bone mineral density (BMD) in women with anorexia nervosaBone, 2008
- Impact of Glucose-Dependent Insulinotropic Peptide on Age-Induced Bone LossJournal of Bone and Mineral Research, 2008
- Role of Gastrointestinal Hormones in Postprandial Reduction of Bone ResorptionJournal of Bone and Mineral Research, 2003
- Hypothalamic Y2 receptors regulate bone formationJournal of Clinical Investigation, 2002